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Abstract 
Review on t(5;14)(q35;q11), with data on clinics 
and the genes involved. 
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Clinics and pathology 
Disease 
Acute lymphoblastic leukemia (ALL) 
Phenotype/cell stem origin 
T- and B-ALL 
Epidemiology 
5 patients to date, 4 pediatric cases (14 months, 2, 
10 and 12 years) (Whitlock JA et al., 1994; Hansen-
Hagge TE et al., 2002), 1 case with no clinical 
information (Hansen-Hagge et al., 2002, case 2) 
Clinics 
One or more features of bulky disease. 
Cytogenetics 
Sole abnormality in one case of T-ALL and one 
case of B-ALL relapse, additional abnormalities in 
2 cases [B-ALL with subclones with 
dup(1)(q32q21), add(X)(p22), der(11)t(11;?)(?;?) 
and T-ALL with cytogenetically unrelated cell line 
with del(9)(p22) and trisomy 15 (t-ALL)], 2 cases  
not available]. 
Evolution 
The 2 patients with B-ALL were in remission 19 
and 22 months after diagnosis. One patient with T-
ALL relapsed at 6 months and the second patient 
with T-ALL developed AML 17 months after 
diagnosis, with the t(5;14) being present in the 
myeloblasts. 
Disease 
Acute myeloid leukemia, FAB M5 (Welborn JL et 
al., 1993) 
Note 
Secondary abnormality. 
Epidemiology 
1 case to date, a 45-year-male. 
Cytogenetics 
The t(5;14)(q35;q11) was found in a follow-up 
specimen together with the primary abnormality, 
t(6;11)(q27;q23), identified in the sample obtained 
at diagnosis. 
Genes 
The genes involved in the translocation t(5;14) 
identified in this AML case have not been 
investigated and may be different from those of the 
t(5;14) found in the ALL cases. 
Treatment 
2 inductions with standard dose cytarabine - 
daunorubicin - 6-thioguanine. 
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Evolution 
No response to treatment. 
Genes involved and 
proteins 
RANBP17 (RAN binding protein 17) 
Location 5q35.1 
Note 
The 5q breakpoint was initially reported to be 
located at 5q34 (Hansen-Hagge et al., 2002), but the 
location of the gene potentially disrupted by the 
translocation is 5q35.1 in the hg38 assembly 
(UCSC Genome Browser, accessed Dec. 9th, 2016). 
However, Harsen-Hagge et al., 2002, mention that 
the 5q breakpoint is also in the vinicity of the TLX3 
gene, which involvement was neither confirmed nor 
excluded. This gene has been involved in other 
ALL rearrangements and encodes a DNA-binding 
nuclear transcription factor (see Atlas 
t(5;7)(q35;q21), t(5;14)(q35;q32)). 
DNA/RNA 
The RANBP17 gene has 28 exons and spans 438 kb 
(hg38, UCSC Genome Browser, accessed Dec. 9th, 
2016). Several transcripts have been identified, of 
2,5, 4,5, 7,5 and 10 kb (Koch et al., 2000). 
Protein 
The Ran-binding protein 17 is 90-130 kD in size 
and contains an importin- β N-terminal domain. 
The RAN-binding protein-17 gene is a member of 
the importin-beta superfamily of nuclear transport 
receptors.  Its protein is localized in the nucleus, 
with a restricted expression pattern in the testis 
(Koch P et al., 2000). It is a regulator of the E2A 
protein's action (Lee et al., 2010). 
TLX3 (T-cell leukemia, homeobox 
protein 3) 
Location  
5q35.1 
TRD 
Location  
14q11.2 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
In one case, exon 24 of RANBP17 was found to be 
joined to TCR Dδ2Dδ3Jδ1 and containing the δ 
enhancer sequence located between the Jδ1 and Cδ 
elements, while in a second case, data suggested an 
illegitimate recombination of TCR δ with 
sequences from chromosome 14 and 5, the 5q 
breakpoint being about 8 kb downstream of the last 
RANBP17 exon (and about 1KB upstream from 
TLX3) . There was an increased RANBP17 
expression in the leukemic cells (Harsen-Hagge et 
al., 2002) . 
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